Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.
Wafaa M EzzatKhalda S AmrSalwa TawfeekHassan ElbataeEman A BayomiAhmed HeibaYasser ElhosaryPublished in: BMC infectious diseases (2024)
The key differentially expressed microRNAs before and after the direct-acting antiviral (DAA) regimen were connected to the dynamics of chronic HCV infection, suggesting their potential as predictive biomarkers for HCV clearance after sofosbuvir and daclatasvir therapy.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- combination therapy
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- stem cells
- risk assessment
- climate change
- mesenchymal stem cells
- hiv infected
- liver fibrosis
- drug induced